APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

CT.gov Identifier
NCT03615235
EudraCT Identifier
N/A
CTIS:
N/A
Sponsor
National Institutes of Health/National Institute of Allergy and Infectious Diseases
Collaborator
Wake Forest University Health Sciences, National Institute of Health & Family Welfare (NIHFW)
Study Contact Information
N/A
Recruiting
Contact Us

Study Details

Diseases
APOL1 Mediated Kidney Disease (AMKD)
Study Drug
No drug
Genes
APOL1
Study Dates
Mar 2019 - May 2027
Sex
Female & Male
Age
N/A
Inclusion and Exclusion Criteria
Inclusion Criteria:
  • Inclusion Criteria for Living Donors:
  • * Living kidney donors with self-reported recent African ancestry (defined as African American, Afro-Caribbean, Hispanic black or African) will be eligible for inclusion.
Exclusion Criteria:
  • for Living Donors:
  • * Participants who are unable or unwilling to provide informed consent.
  • Enrollment and bio sample collection from deceased donors at OPOs ended on May 31, 2023 and recruiting kidney transplant recipients ended on June 15, 2023.
  • Phase II started on 9/1/2023 and only Living Donors will be recruited for an additional 2 years.

Protocol Summary

The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

Study Locations

To view all trial locations, click here

Contact Us About More Information for the Clinical Trial Concierge Service

Natera’s Clinical Trial Concierge Program is comprised of a dedicated team that helps connect providers and patients with appropriate clinical trials. To learn more about a trial offered through this service, please complete the form below.  

Fields marked with asterisk (*) are mandatory.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.